Compare BOOM & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOOM | VRCA |
|---|---|---|
| Founded | 1965 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.8M | 107.5M |
| IPO Year | 1995 | 2018 |
| Metric | BOOM | VRCA |
|---|---|---|
| Price | $5.93 | $5.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $8.50 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 384.9K | 31.3K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.02 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $609,840,000.00 | $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.55 | $94.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $4.69 | $3.28 |
| 52 Week High | $9.20 | $9.82 |
| Indicator | BOOM | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 39.08 | 36.85 |
| Support Level | $5.55 | $4.25 |
| Resistance Level | $6.50 | $6.53 |
| Average True Range (ATR) | 0.29 | 0.40 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 4.30 | 2.40 |
DMC Global Inc operates a diversified family of technical product and process businesses serving the energy, industrial and infrastructure markets. Its business is organized into three segments: Arcadia, DynaEnergetics, and NobelClad. Arcadia Products supplies architectural building products, including exterior and interior framing systems, windows, urtain walls, storefronts etc to the commercial construction market. NobelClad is involved in the production of explosion-welded clad metal plates for use in the construction of corrosion-resistant industrial processing equipment and specialized transition joints. DynaEnergetics driver, designs manufactures and distributes products utilized by the oil and gas industry principally for the perforation of oil and gas wells.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.